RU2014152445A - Композиции на основе диклофенака - Google Patents
Композиции на основе диклофенака Download PDFInfo
- Publication number
- RU2014152445A RU2014152445A RU2014152445A RU2014152445A RU2014152445A RU 2014152445 A RU2014152445 A RU 2014152445A RU 2014152445 A RU2014152445 A RU 2014152445A RU 2014152445 A RU2014152445 A RU 2014152445A RU 2014152445 A RU2014152445 A RU 2014152445A
- Authority
- RU
- Russia
- Prior art keywords
- mass
- composition
- amount
- composition according
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 44
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims abstract 6
- 229960001259 diclofenac Drugs 0.000 title claims abstract 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 18
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract 13
- 239000003963 antioxidant agent Substances 0.000 claims abstract 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract 10
- 150000005846 sugar alcohols Polymers 0.000 claims abstract 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract 6
- -1 diethylene glycol monoalkyl ether Chemical class 0.000 claims abstract 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims abstract 6
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract 6
- 239000003349 gelling agent Substances 0.000 claims abstract 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims abstract 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims abstract 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002904 solvent Substances 0.000 claims abstract 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940051250 hexylene glycol Drugs 0.000 claims abstract 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims 8
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 6
- 229940043348 myristyl alcohol Drugs 0.000 claims 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 4
- 229940001584 sodium metabisulfite Drugs 0.000 claims 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000000473 propyl gallate Substances 0.000 claims 3
- 229940075579 propyl gallate Drugs 0.000 claims 3
- 235000010388 propyl gallate Nutrition 0.000 claims 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176115 | 2012-07-12 | ||
| EP12176115.9 | 2012-07-12 | ||
| PCT/EP2013/064123 WO2014009241A1 (en) | 2012-07-12 | 2013-07-04 | Diclofenac formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014152445A true RU2014152445A (ru) | 2016-08-27 |
Family
ID=48741196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014152445A RU2014152445A (ru) | 2012-07-12 | 2013-07-04 | Композиции на основе диклофенака |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9999590B2 (enExample) |
| EP (2) | EP3275466A1 (enExample) |
| JP (2) | JP6259454B2 (enExample) |
| KR (1) | KR20150030752A (enExample) |
| CN (1) | CN104428003B (enExample) |
| AU (1) | AU2013289403B2 (enExample) |
| BR (1) | BR112015000329A2 (enExample) |
| CA (1) | CA2878784A1 (enExample) |
| HK (1) | HK1204973A1 (enExample) |
| IL (1) | IL236304A0 (enExample) |
| MX (1) | MX2015000541A (enExample) |
| NZ (1) | NZ702967A (enExample) |
| RU (1) | RU2014152445A (enExample) |
| WO (1) | WO2014009241A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10813897B2 (en) * | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| NZ702967A (en) * | 2012-07-12 | 2017-07-28 | Ferring Bv | Diclofenac formulations |
| US9855234B2 (en) * | 2014-07-08 | 2018-01-02 | Insys Development Company, Inc. | Diclofenac sublingual spray |
| JP7069042B2 (ja) | 2016-12-28 | 2022-05-17 | 久光製薬株式会社 | 貼付剤 |
| JP7109093B2 (ja) * | 2017-01-31 | 2022-07-29 | 帝國製薬株式会社 | リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画 |
| JP7250689B2 (ja) * | 2017-03-07 | 2023-04-03 | イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド | 活性化合物のための局所送達系 |
| KR20190101140A (ko) * | 2018-02-22 | 2019-08-30 | 동아제약 주식회사 | 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물 |
| JP7053790B2 (ja) | 2018-02-27 | 2022-04-12 | 久光製薬株式会社 | ジクロフェナク含有乳化ゲル組成物 |
| US20210386858A1 (en) * | 2019-02-19 | 2021-12-16 | Bluepharma - Industria Farmacêutica, S.A. | Mucoadhesive compositions and uses thereof |
| JP6744512B1 (ja) * | 2020-02-12 | 2020-08-19 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
| JP6761553B1 (ja) * | 2020-02-12 | 2020-09-23 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
| BR112022016887A2 (pt) | 2020-02-27 | 2022-10-18 | Ferring Bv | Composições tópicas de diclofenaco e métodos |
| JP2022096994A (ja) * | 2020-12-18 | 2022-06-30 | 小林製薬株式会社 | 外用医薬組成物 |
| US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
| IT202100016751A1 (it) * | 2021-06-25 | 2022-12-25 | Altergon Sa | Formulazione topica di diclofenac ad elevato tasso di assorbimento |
| JP2024538604A (ja) | 2021-10-01 | 2024-10-23 | ニュートリション・アンド・バイオサイエンシーズ・ユーエスエー・ワン，エルエルシー | 局所適用のための親水コロイドブレンド組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| PE20040321A1 (es) | 2002-08-22 | 2004-07-15 | Novartis Consumer Health Sa | Composicion topica que comprende diclofenaco |
| US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0524958D0 (en) | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Transdermal administration of active agents |
| DK2347775T3 (da) | 2005-12-13 | 2020-07-13 | Harvard College | Skabeloner til celletransplantation |
| TW200815045A (en) | 2006-06-29 | 2008-04-01 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of ropinirole and methods of use thereof |
| EP2055298A1 (en) * | 2007-10-30 | 2009-05-06 | Novartis AG | Topical composition |
| US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
| EP2364140A1 (en) | 2008-11-28 | 2011-09-14 | Advance Holdings Limited | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| KR20110127678A (ko) | 2009-03-11 | 2011-11-25 | 코와 가부시키가이샤 | 진통·항염증제 함유 외용제 |
| EP2552418B1 (en) | 2010-03-29 | 2017-08-09 | Ferring B.V. | A fast dissolving pharmaceutical composition |
| NZ702967A (en) * | 2012-07-12 | 2017-07-28 | Ferring Bv | Diclofenac formulations |
-
2013
- 2013-07-04 NZ NZ702967A patent/NZ702967A/en not_active IP Right Cessation
- 2013-07-04 KR KR20157003028A patent/KR20150030752A/ko not_active Withdrawn
- 2013-07-04 CN CN201380036305.1A patent/CN104428003B/zh active Active
- 2013-07-04 BR BR112015000329A patent/BR112015000329A2/pt active Search and Examination
- 2013-07-04 EP EP17190099.6A patent/EP3275466A1/en not_active Withdrawn
- 2013-07-04 AU AU2013289403A patent/AU2013289403B2/en not_active Ceased
- 2013-07-04 US US14/413,922 patent/US9999590B2/en active Active
- 2013-07-04 RU RU2014152445A patent/RU2014152445A/ru not_active Application Discontinuation
- 2013-07-04 MX MX2015000541A patent/MX2015000541A/es unknown
- 2013-07-04 HK HK15105792.2A patent/HK1204973A1/xx unknown
- 2013-07-04 WO PCT/EP2013/064123 patent/WO2014009241A1/en not_active Ceased
- 2013-07-04 JP JP2015520915A patent/JP6259454B2/ja active Active
- 2013-07-04 EP EP13733003.1A patent/EP2872177B1/en not_active Not-in-force
- 2013-07-04 CA CA2878784A patent/CA2878784A1/en not_active Abandoned
-
2014
- 2014-12-16 IL IL236304A patent/IL236304A0/en unknown
-
2017
- 2017-09-22 JP JP2017182383A patent/JP6434104B2/ja active Active
-
2018
- 2018-05-18 US US15/983,911 patent/US10117829B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104428003A (zh) | 2015-03-18 |
| CN104428003B (zh) | 2020-03-10 |
| HK1204973A1 (en) | 2015-12-11 |
| JP2018048140A (ja) | 2018-03-29 |
| EP2872177A1 (en) | 2015-05-20 |
| WO2014009241A1 (en) | 2014-01-16 |
| US20150297507A1 (en) | 2015-10-22 |
| JP6259454B2 (ja) | 2018-01-10 |
| CA2878784A1 (en) | 2014-01-16 |
| US10117829B2 (en) | 2018-11-06 |
| EP2872177B1 (en) | 2017-12-20 |
| EP3275466A1 (en) | 2018-01-31 |
| AU2013289403A1 (en) | 2015-01-22 |
| US20180263897A1 (en) | 2018-09-20 |
| MX2015000541A (es) | 2015-05-11 |
| JP6434104B2 (ja) | 2018-12-05 |
| US9999590B2 (en) | 2018-06-19 |
| KR20150030752A (ko) | 2015-03-20 |
| AU2013289403B2 (en) | 2017-05-11 |
| JP2015522049A (ja) | 2015-08-03 |
| BR112015000329A2 (pt) | 2017-06-27 |
| IL236304A0 (en) | 2015-02-26 |
| NZ702967A (en) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014152445A (ru) | Композиции на основе диклофенака | |
| JP2015522049A5 (enExample) | ||
| RU2013133082A (ru) | Композиции тестостерона | |
| BR112022004495A2 (pt) | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| RU2015107733A (ru) | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения | |
| CN104274433B (zh) | 咖啡酸酰胺衍生物的应用 | |
| HRP20211303T1 (hr) | Pripravci koji sadrže silimarin i sulfoalkil eter ciklodekstrin i postupci korištenja istih | |
| RU2015115723A (ru) | Кетопрофеновая композиция для местного применения | |
| RU2015122627A (ru) | Кожные композиции, содержащие неприродные гигроскопические аминокислоты | |
| RU2011137530A (ru) | Лечение кожи | |
| AR074309A1 (es) | Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo | |
| CO2024017138A2 (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| HRP20231241T1 (hr) | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa | |
| EP3294267A1 (en) | Compositions for treating and/or preventing psoriasis, prickly heat, dermatitises, neurofibromatosis type 1 and other pathologies of the dermis, mucosae, and oral cavity | |
| TWI712408B (zh) | 外用醫藥組成物 | |
| CN105411998B (zh) | 含有五味子乙素的治疗烧烫伤的外用组合物 | |
| MX2014006051A (es) | Uso de alcoholes pegilados para el tratamiento de queratosis actinica. | |
| JP2022534264A (ja) | フルオキセチンとビタミンｄ３またはその誘導体を含有する組成物およびその用途 | |
| US8680326B2 (en) | Pharmaceutical compositions and therapeutic applications of a hydrocortisone derivative designated as deina | |
| WO2014014389A3 (ru) | Композиция в форме геля для профилактики и лечения пародонта | |
| US20200315930A1 (en) | Composition for topical skin care | |
| ES2632591T3 (es) | Tratamiento de la seborrea | |
| RU2274451C1 (ru) | Мазь для лечения дерматомикозов животных и человека | |
| CN101259138A (zh) | 局部应用于动物运动系统部位的消炎和镇痛组合物 | |
| RU2706234C2 (ru) | Применение гидроксида калия при лечении актинического кератоза |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180314 |